EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network

Mirna Chehade, Sheridan Meyers, Talaya McCright-Gill, Rogerwene Gifford, Mustafa Sahin, Michael E Shy, Michele Manion, Dakota Campbell, Marc E Rothenberg, Maurizio Macaluso

Clinical and Translational Science · 2026-06 · 19 (6)

DOI: 10.1111/cts.70585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 17.05.2026. Verfasst von Mirna Chehade und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Biomedical Research, Intersectoral Collaboration, Rare Diseases, Translational Research, Biomedical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Rare Diseases Clinical Research Network (RDCRN) was established to improve diagnosis, treatment, and research collaboration across rare diseases through collaborative, multi‐site, translational, and clinical research. Its governance framework promotes efficient data sharing and collaboration among research consortia, NIH representatives, and patient advocacy groups (PAGs). This infrastructure facilitates coordinated efforts to advance rare disease research through shared resources and communication. Prompted by the COVID‐19 pandemic's impact on rare disease patients, the RDCRN recognized cross‐consortia collaboration as a priority. Its policies promote data sharing while protecting participant confidentiality. PAGs participate in governance, study design, and regulatory discussions, helping to identify patient‐relevant priorities, improve recruitment and retention, and strengthen trust between researchers and patients. Cross‐consortia efforts have addressed challenges like biomarker identification and harmonization of clinical measures, leading to new methods and standardized data collection that benefit multiple rare diseases. Studies by teams focusing on different diseases have led to improved diagnostic tools by addressing overlapping disease presentations. The RDCRN offers scholars cross‐consortia opportunities for presentations, competitions, and NIH training collaborations, fostering growth and networking. Network meetings promote exchange and process standardization; pilot projects facilitate independent grant submissions, forming a pipeline of skilled investigators. The RDCRN fosters trust, shared vision, and open communication by cultivating a culture of mutual respect, shared learning, and collective problem solving. By engaging a wide range of stakeholders, it has aligned its research with patient needs, advancing innovation. Its high‐impact publications, effective mentoring programs, and pioneering cross‐consortia initiatives underscore the value of collaboration in rare disease research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomedical ResearchIntersectoral CollaborationRare DiseasesTranslational Research, BiomedicalHumansCooperative BehaviorInformation DisseminationNational Institutes of Health (U.S.)Patient AdvocacyUnited States

Stichwörter der Autor:innen

collaborationcommitteeconsortiumnetworkrare disease

Autor:innen und Institutionen

  • Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Rosamund Stone Zander and Hansjoerg Wyss Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Carver College of Medicine, Department of Neurology, University of Iowa, Iowa City, Iowa, USA.
  • PCD Foundation, Minneapolis, Minnesota, USA.
  • Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Zitieren

APA

Chehade, M., Meyers, S., McCright-Gill, T., Gifford, R., Sahin, M., Shy, M. E., Manion, M., Campbell, D., Rothenberg, M. E., & Macaluso, M. (2026). Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70585

Vancouver

Chehade M, Meyers S, McCright-Gill T, Gifford R, Sahin M, Shy ME, et al. Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70585

BibTeX
@article{Chehade2026,
  author = {Chehade, Mirna and Meyers, Sheridan and McCright-Gill, Talaya and Gifford, Rogerwene and Sahin, Mustafa and Shy, Michael E and Manion, Michele and Campbell, Dakota and Rothenberg, Marc E and Macaluso, Maurizio},
  title = {Collaboration as a Catalyst for Advancing Rare Disease Research: The Experience of the Rare Diseases Clinical Research Network},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {6},
  doi = {10.1111/cts.70585}
}
Kostenlos starten →